Indian markets extended their losing streak for a third day as soaring oil prices and Middle East tensions hurt sentiment. Sensex fell 813 ...

Indian equities extended their decline on Tuesday, with Sensex falling 555 points and Nifty ending below 23,650. Analysts cited elevated cr...

Sensex and Nifty extended their four-week losing streak as rising oil prices and US-Iran tensions weighed on sentiment. Analysts flagged do...

Indian midcap and smallcap indices are near record highs currently. A few select stocks are driving most of these significant gains. This c...

The stock market saw marked declines on Monday, particularly among smallcap and midcap shares. Persistent Systems and National Aluminium Co...

Indian equity markets closed higher on Friday, ending a losing streak with IT stock gains. HDFC Bank's CEO will not seek reappointment, whi...

US Ambassador Sergio Gor met Piramal Group Chairman Ajay Piramal discussing economic ties. Gor lauded Piramal's growing United States footp...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Admini...

Piramal Pharma will focus on policy actions amid tariff concerns. Its global manufacturing network offers a significant advantage. The comp...

Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...

Piramal Pharma's US facility inspection concluded with four observations from the FDA. The company expects a voluntary action indicated cla...

Piramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO business. The co...

Piramal Pharma Q3 Results: Revenue from operations rose 14% YoY driven by double digit growth across all the three businesses.

Piramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...

Piramal Pharma said while the YoY financials are not strictly comparable due to the non-inclusion of certain "non-common control transactio...

The brokerage firm Jefferies assigned buy rating to Piramal Pharma with a target price of Rs 150, implying an upside potential of 20% from ...